NASDAQ:RCKT Rocket Pharmaceuticals Q3 2025 Earnings Report $2.61 +0.01 (+0.38%) Closing price 04:00 PM EasternExtended Trading$2.61 0.00 (0.00%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Rocket Pharmaceuticals EPS ResultsActual EPS-$0.45Consensus EPS -$0.48Beat/MissBeat by +$0.03One Year Ago EPS-$0.71Rocket Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$0.33 millionBeat/MissN/AYoY Revenue GrowthN/ARocket Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time7:00AM ETUpcoming EarningsRocket Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Rocket Pharmaceuticals Earnings HeadlinesRocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?September 22, 2026 | insidermonkey.comChardan Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)September 18, 2026 | theglobeandmail.comShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-free qualified withdrawals, and no lifetime required minimum distributions. The catch: converting triggers ordinary income tax in the year you convert, and the decision cannot be reversed. The right move depends on your income, tax bracket, and retirement timeline.September 28 at 1:00 AM | SmartAsset (Ad)Wedbush Reiterates "Outperform" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)September 18, 2026 | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) Raised to Buy at Needham & Company LLCSeptember 18, 2026 | americanbankingnews.comRocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comSee More Rocket Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rocket Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rocket Pharmaceuticals and other key companies, straight to your email. Email Address About Rocket PharmaceuticalsRocket Pharmaceuticals (NASDAQ:RCKT) is a biotechnology company focused on developing gene therapies for rare and devastating diseases. The company uses lentiviral and adeno-associated virus (AAV) vector platforms to deliver genetic material intended to address the underlying causes of inherited disorders, with research programs spanning hematology, immunology, metabolic disease and cardiac conditions. Rocket’s pipeline has included RP-L102 for Fanconi anemia, a rare inherited bone marrow failure disorder; RP-L201 for leukocyte adhesion deficiency-I, an immune-system disorder; and RP-L301 for pyruvate kinase deficiency, a rare red blood cell disorder. The company has also developed cardiac gene therapy programs, including RP-A501 for Danon disease, a genetic condition that can cause severe cardiomyopathy. Program status and development plans may change as clinical studies and regulatory reviews progress. Rocket Pharmaceuticals was formerly known as InoMed Pharmaceuticals and adopted its current name in 2015. The company is headquartered in Cranbury, New Jersey, and conducts research, clinical development and regulatory activities in collaboration with medical institutions and partners in the United States and other international markets. Its leadership has included Gaurav Shah, M.D., as chief executive officer.View Rocket Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
